Chief Executive Officer

Chief Financial Officer

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

Jade Biosciences Announces $135 Million Private Placement

Jade Biosciences announces JADE201 afucosylated monoclonal antibody

Jade Biosciences prices 13.4M shares at $9.14 in private placement

Director, Clinical Operations

Jade Biosciences is focused on developing innovative therapies for autoimmune diseases, including their lead candidate for chronic kidney disease. The Director of Clinical Operations will oversee clinical trials, manage budgets, and collaborate with cross-functional teams while mentoring staff and ensuring successful trial execution.

Sign up with Google

Sign in with Google